| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
GX1 Stock Overview
genXone S.A. develops products and solutions based on nucleic acid sequencing technologies in Poland and internationally.
genXone Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł14.92 |
| 52 Week High | zł34.50 |
| 52 Week Low | zł13.02 |
| Beta | 0 |
| 1 Month Change | -10.66% |
| 3 Month Change | -3.12% |
| 1 Year Change | -38.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.30% |
Recent News & Updates
Investors Holding Back On genXone S.A. (WSE:GX1)
With a price-to-earnings (or "P/E") ratio of 8.6x genXone S.A. ( WSE:GX1 ) may be sending bullish signals at the...
Shareholder Returns
| GX1 | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -0.3% | -2.3% | 1.3% |
| 1Y | -38.9% | -41.8% | -17.1% |
Return vs Industry: GX1 exceeded the Polish Biotechs industry which returned -41.8% over the past year.
Return vs Market: GX1 underperformed the Polish Market which returned -17.1% over the past year.
Price Volatility
| GX1 volatility | |
|---|---|
| GX1 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in PL Market | 13.6% |
| 10% least volatile stocks in PL Market | 4.5% |
Stable Share Price: GX1 is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GX1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | Michal Kaszuba | https://www.genxone.eu |
genXone S.A. develops products and solutions based on nucleic acid sequencing technologies in Poland and internationally. The company specializes in next generation sequencing and medical diagnostics. It uses nanopore sequencing technology in the areas of science, business, and medicine; and specializes in the field of microbiome research, multi-genetic diseases, RNA, genomics, metagenomics, transcriptomics of bacteriophages, nutrigenomics, genetics of metabolic diseases, molecular ecology, and genetic engineering and bioinformatics.
genXone Fundamentals Summary
| GX1 fundamental statistics | |
|---|---|
| Market Cap | zł49.16m |
| Earnings (TTM) | zł8.65m |
| Revenue (TTM) | zł25.19m |
5.7x
P/E Ratio2.0x
P/S RatioIs GX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GX1 income statement (TTM) | |
|---|---|
| Revenue | zł25.19m |
| Cost of Revenue | zł9.21m |
| Gross Profit | zł15.98m |
| Other Expenses | zł7.33m |
| Earnings | zł8.65m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 12, 2022
| Earnings per share (EPS) | 2.62 |
| Gross Margin | 63.43% |
| Net Profit Margin | 34.34% |
| Debt/Equity Ratio | 0.0% |
How did GX1 perform over the long term?
See historical performance and comparisonDividends
6.7%
Current Dividend Yield38%
Payout RatioDoes GX1 pay a reliable dividends?
See GX1 dividend history and benchmarks| genXone dividend dates | |
|---|---|
| Ex Dividend Date | Jun 17 2022 |
| Dividend Pay Date | Jul 04 2022 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 36 days |
Does GX1 pay a reliable dividends?
See GX1 dividend history and benchmarksValuation
Is genXone undervalued compared to its fair value and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GX1 (PLN14.92) is trading below our estimate of fair value (PLN222.17)
Significantly Below Fair Value: GX1 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GX1 is good value based on its Price-To-Earnings Ratio (5.7x) compared to the Polish Biotechs industry average (34.9x).
PE vs Market: GX1 is good value based on its Price-To-Earnings Ratio (5.7x) compared to the Polish market (10x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GX1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GX1 is good value based on its Price-To-Book Ratio (2.1x) compared to the PL Biotechs industry average (3.8x).
Future Growth
How is genXone forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
42.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as genXone has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has genXone performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
81.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GX1 has high quality earnings.
Growing Profit Margin: GX1's current net profit margins (34.3%) are lower than last year (35.6%).
Past Earnings Growth Analysis
Earnings Trend: GX1's earnings have grown significantly by 81.1% per year over the past 5 years.
Accelerating Growth: GX1's earnings growth over the past year (5.1%) is below its 5-year average (81.1% per year).
Earnings vs Industry: GX1 earnings growth over the past year (5.1%) exceeded the Biotechs industry -6.2%.
Return on Equity
High ROE: GX1's Return on Equity (36.9%) is considered high.
Financial Health
How is genXone's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: GX1's short term assets (PLN19.0M) exceed its short term liabilities (PLN3.4M).
Long Term Liabilities: GX1's short term assets (PLN19.0M) exceed its long term liabilities (PLN104.4K).
Debt to Equity History and Analysis
Debt Level: GX1 is debt free.
Reducing Debt: GX1 had no debt 5 years ago.
Debt Coverage: GX1 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GX1 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is genXone current dividend yield, its reliability and sustainability?
Dividend Score
2/6Dividend Score 2/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
6.70%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: GX1's dividend (6.7%) is higher than the bottom 25% of dividend payers in the Polish market (2.63%).
High Dividend: GX1's dividend (6.7%) is low compared to the top 25% of dividend payers in the Polish market (7.73%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether GX1's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if GX1's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (38.1%), GX1's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (29.8%), GX1's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Michal Kaszuba
no data
Tenure
Dr. Michal Kaszuba is President of the Board at genXone S.A. He is the main originator, co-founder of the genXone S.A. He is a graduate of the University of Warmia and Mazury in Olsztyn (Faculty of Biology...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
genXone S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: genXone S.A.
- Ticker: GX1
- Exchange: WSE
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł49.161m
- Shares outstanding: 3.30m
- Website: https://www.genxone.eu
Number of Employees
Location
- genXone S.A.
- ul. Kobaltowa 6
- Zlotniki
- Suchy Las
- 60-002
- Poland
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/28 00:00 |
| End of Day Share Price | 2022/05/27 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.